PTI-202 / Filana Therapeutics - LARVOL DELTA

EMPATHI Study: Real-World Evidence on Adult ITP Management, Treatment Response, and Patient Burden in Spain (ISTH 2026) - "TPO ‑ RAs remain the preferred option in second ‑ line treatment, while rituximab plays a residual role. The most frequently used average weekly doses are: eltrombopag 350mg (72%), avatrombopag 140mg (72%), fostamatinib 1400mg (52%), and romiplostim 3-4 μg/kg (40% each)...Current Treatment Patterns by Line of Therapy Page 2 Table or Figure Upload (2) Figure 1. Response rate of ITP patients per product and line according to the GEPTI 2023 guidelines DOI*10.1016/j.rpth.2026.104431"

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Dyslipidemia • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Metabolic Disorders • Pulmonary Arterial Hypertension • Thrombocytopenia • Thrombocytopenic Purpura

"retweet survey @PTIofficial @ImranKhanPTI @AsadQaiserPTI @dolly_qureshi @shiblifaraz @FaisalJavedKhan @MuradSaeedPTI @thefixxinco @Ali_MuhammadPTI @RajaBasharatLAW @Multan_PTI2020 @PTI_TIGERS4 @PTIadil1 @Karachi__Wali @WasifHasan19 @RBH_PTI @AmmaraZahid4 @NailaUsmani1 @APPNA" (,@sehbaia)

"Retweet @p4pakipower @PTIKPOfficial @PTI_TIGERS4 @pti @FatimaPTI_IK @Multan_PTI2020 @Rabbia112233 @Karachi__Wali @PTIadil1 @PTIadil1 @Waqasalinew @naziarubbani @ptifamily @KhalidaMehmood6 @PTIOfficialRWP @AmmaraZahid4 @PTIOfficialSKT @IlyasKhalil20 @pti_saeen @PTIVideos" (,@sehbaia)

"retweet @ImranKhanPTI @SMQureshiPTI @Ali_MuhammadPTI @AliHZaidiPTI @AndleebAbbas @PTIOkaara @ZiaBangashPTI @ptilawyer1 @Multan_PTI2020 @PTILahorePunjab @AliAminKhanPTI @OfficialDGISPR @dgprPaknavy @ArifAlvi @" (,@sehbaia)

"Thanks @shona_brierton for all your help with #kisspeptin2022 and #icn2022" (,@WaljitD)

"Tamperelaisen Anssi Räntilän kokeilut uuden #kaurapasta'n kehityksessä eivät menneet aivan putkeen. 😅 Luomisen tuskaa Suomalainen #Menestysresepti 2021 -kisassa. Hyvä #pasta siitä tulee! 🤟 » Lue lisää: https://t.co/h1vsfWCU49 #innovaatio #Maikkari #SMR2021 #ruoka #kauppa" (,@sryhma)

Pain Therapeutics reports Pfizer elects to continue development of Remoxy (Pain Therapeutics Press Release) - "Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported Pfizer Inc. (NYSE:PFE) has informed us that, having achieved technical milestones related to manufacturing, they will continue the development program for REMOXY® (oxycodone) Extended-Release Capsules CII....The complete response submission is not expected to occur prior to mid-2015....Pfizer has returned to us all rights with respect to abuse-resistant formulations of hydrocodone, hydromorphone and oxymorphone....We are now free to develop and commercialize these assets on our own or with a licensee of our choice, and may do so without notice or approval from Pfizer."

Anticipated FDA event • Pipeline update • Pain